A detailed history of Natixis Advisors, L.P. transactions in Novo Nordisk A S stock. As of the latest transaction made, Natixis Advisors, L.P. holds 3,074,876 shares of NVO stock, worth $269 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares
3,074,876
Previous 2,994,806 2.67%
Holding current value
$269 Million
Previous $427 Million 14.35%
% of portfolio
0.71%
Previous 0.93%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$119.07 - $145.42 $9.53 Million - $11.6 Million
80,070 Added 2.67%
3,074,876 $366 Million
Q2 2024

Aug 01, 2024

BUY
$122.71 - $146.91 $103,812 - $124,285
846 Added 0.03%
2,994,806 $427 Million
Q1 2024

Apr 25, 2024

SELL
$102.11 - $135.92 $5.97 Million - $7.94 Million
-58,446 Reduced 1.91%
2,993,960 $384 Million
Q4 2023

Feb 06, 2024

BUY
$87.78 - $105.45 $4.86 Million - $5.83 Million
55,333 Added 1.85%
3,052,406 $316 Million
Q3 2023

Nov 13, 2023

BUY
$90.94 - $199.54 $134 Million - $293 Million
1,469,489 Added 96.2%
2,997,073 $273 Million
Q2 2023

Aug 15, 2023

BUY
$155.98 - $172.65 $3.43 Million - $3.79 Million
21,980 Added 1.46%
1,527,584 $247 Million
Q1 2023

May 11, 2023

BUY
$132.34 - $159.14 $6.26 Million - $7.52 Million
47,277 Added 3.24%
1,505,604 $240 Million
Q4 2022

Jan 27, 2023

SELL
$102.55 - $135.33 $2.62 Million - $3.46 Million
-25,593 Reduced 1.72%
1,458,327 $197 Million
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $7.19 Million - $8.83 Million
75,498 Added 5.36%
1,483,920 $148 Million
Q2 2022

Aug 12, 2022

BUY
$103.24 - $121.81 $20.9 Million - $24.7 Million
202,645 Added 16.81%
1,408,422 $157 Million
Q1 2022

May 12, 2022

BUY
$93.1 - $112.54 $17.8 Million - $21.5 Million
190,713 Added 18.79%
1,205,777 $134 Million
Q4 2021

Feb 08, 2022

SELL
$95.88 - $117.08 $26.3 Million - $32.2 Million
-274,788 Reduced 21.3%
1,015,064 $114 Million
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $26.5 Million - $33.4 Million
313,585 Added 32.12%
1,289,852 $124 Million
Q2 2021

Aug 12, 2021

SELL
$67.66 - $84.76 $1.24 Million - $1.55 Million
-18,256 Reduced 1.84%
976,267 $81.8 Million
Q1 2021

May 05, 2021

BUY
$67.06 - $75.82 $4.38 Million - $4.95 Million
65,330 Added 7.03%
994,523 $67.1 Million
Q4 2020

Feb 12, 2021

SELL
$63.89 - $73.8 $7.69 Million - $8.88 Million
-120,346 Reduced 11.47%
929,193 $64.9 Million
Q3 2020

Nov 12, 2020

SELL
$63.69 - $70.22 $1.56 Million - $1.72 Million
-24,458 Reduced 2.28%
1,049,539 $72.9 Million
Q2 2020

Aug 11, 2020

SELL
$58.54 - $67.94 $25.7 Million - $29.9 Million
-439,625 Reduced 29.04%
1,073,997 $70.3 Million
Q1 2020

Apr 27, 2020

SELL
$49.46 - $64.78 $9.83 Million - $12.9 Million
-198,846 Reduced 11.61%
1,513,622 $91.1 Million
Q4 2019

Feb 10, 2020

SELL
$49.86 - $58.26 $3.38 Million - $3.94 Million
-67,704 Reduced 3.8%
1,712,468 $99.1 Million
Q3 2019

Nov 12, 2019

SELL
$47.54 - $53.43 $3.25 Million - $3.65 Million
-68,329 Reduced 3.7%
1,780,172 $92 Million
Q2 2019

Aug 12, 2019

BUY
$46.79 - $52.47 $256,736 - $287,902
5,487 Added 0.3%
1,848,501 $94.3 Million
Q1 2019

May 15, 2019

BUY
$46.36 - $52.63 $2.82 Million - $3.2 Million
60,802 Added 3.41%
1,843,014 $96.4 Million
Q4 2018

Feb 13, 2019

BUY
$41.54 - $47.25 $76,932 - $87,507
1,852 Added 0.1%
1,782,212 $82.1 Million
Q3 2018

Nov 13, 2018

BUY
$46.76 - $51.24 $11.7 Million - $12.8 Million
249,822 Added 16.32%
1,780,360 $83.9 Million
Q2 2018

Aug 14, 2018

SELL
$44.29 - $50.42 $9.2 Million - $10.5 Million
-207,820 Reduced 11.95%
1,530,538 $0
Q1 2018

May 10, 2018

SELL
$48.49 - $58.14 $1.21 Million - $1.46 Million
-25,054 Reduced 1.42%
1,738,358 $85.6 Million
Q4 2017

Feb 14, 2018

BUY
$47.53 - $53.73 $2.53 Million - $2.86 Million
53,188 Added 3.11%
1,763,412 $94.6 Million
Q3 2017

Nov 14, 2017

BUY
$41.15 - $49.22 $70.4 Million - $84.2 Million
1,710,224
1,710,224 $82.3 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.